Secondary analysis of a randomised phase 2 trial in 110 patients with metastatic clear cell renal cell carcinoma: low ipilimumab trough level was linked to worse PFS with nivolumab plus ipilimumab (HR 1.77); nivolumab levels were not; neither predicted death or grade ≥3 TRAEs.
Secondary analysisn = 110
Blanchet et al. Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study